Mutations reported to render Erks active, primarily gain-of-function mutants, were found to possess no intrinsic catalytic capabilities ([e.g., sevenmaker (36), mutations identified in cancer patients [E320K in ERK2] [mutation ID in ERK2, COSM461148] (35, 37)). Here, MAPK1 is linked to cancer.